On this week’s episode, Meg Rivers, editor-in-chief, and Miranda Schmalfuhs, group social media editor, speak with Steve Paul, chairman of the board, president, and CEO of Karuna Therapeutics, as well as Andrew Miller, founder and chief operating officer of Karuna Therapeutics. Miller was also one of Pharm Exec’s 2020 Emerging Pharma Leaders.
The editors speak with Paul and Miller about the following: 1) their journey into pharma; 2) the factors that impact their decision to pursue any individual drug product; 3) the mental health/disorder treatment landscape; 4) what treatment has been like, historically, for schizophrenia and psychosis in Alzheimer's disease; 5) the company’s drug, KarXT, which is being evaluated in schizophrenia and psychosis in Alzheimer's disease; and 6) potential marketing and commercialization challenges for KarXT.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
